More on LEGN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+166.7% Growth)
- Ratings (8.3 Score)
- Holders

Upcoming Events

- Earnings (8/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Legend Biotech (NQ:LEGN)
Delayed: 33.52 --0 (-0%)
Prev. Close $33.52  
Open$33.52 
52 Wk High$ 
52 Wk Low$ 
Day High$33.52 
Day Low$33.52 
P/E N/A  
EPS$ 
Volume109,070 

Friends, Peers and Foes (?): GILD, ASND, 0A3M, INSM, MRNA (more...)

Jun 17, 2026 09:22 PM Legend Biotech prices $226 million public offering of ADS shares
Jun 17, 2026 09:21 PM Legend Biotech Corporation Announces Pricing of Public Offering
Jun 17, 2026 04:50 PM Form 424B5 Legend Biotech Corp
Jun 17, 2026 04:43 PM Form F-6EF Legend Biotech Corp Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary
Jun 17, 2026 04:29 PM Legend Biotech launches $225 million ADS public offering
Jun 17, 2026 04:29 PM Legend Biotech Corporation Announces Proposed Public Offering 
Jun 15, 2026 08:00 AM Form 6-K Legend Biotech Corp For: Jun 15
Jun 15, 2026 08:00 AM Legend Biotech reports early trial results for in vivo CAR-T therapy
Jun 15, 2026 08:00 AM Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Jun 14, 2026 08:12 AM Legend Biotech reports early clinical trial results for LB2501 therapy
View All Articles

Entities mentioned with LEGN

View All Entities